Akshay Vaishnaw, EVP, R&D at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 66,532 shares at $121.69 ($8.1M) on 2017-10-30, disclosed to the SEC on 2017-11-01.
Open-market sale of $8.1M ALNY by EVP, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $119.79 | 800 | $96K | 1.2% |
| 2 | $120.78 | 11,418 | $1.4M | 17.1% |
| 3 | $120.78 | 11,418 | $1.4M | 17.1% |
| 4 | $121.69 | 17,755 | $2.2M | 26.7% |
| 5 | $121.69 | 17,755 | $2.2M | 26.7% |
| 6 | $122.79 | 3,693 |
| $453K |
| 5.6% |
| 7 | $122.79 | 3,693 | $453K | 5.6% |
| Total | $121.48 avg | 66,532 | $8.1M | 100% |
| Filing → |
| SRRK | SELL | 2025-05-30 | $353K | — | Filing → |
| ALNY | SELL | 2023-08-07 | $1.4M | — | Filing → |
| ALNY | SELL | 2023-04-28 | $839K | — | Filing → |